Interactions of Platelets, Macrophages, and Lipoproteins in Hypercholesterolemia: Antiatherogenic Effects of HMG-CoA Reductase Inhibitor Therapy
- 1 January 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 31 (1), 39-45
- https://doi.org/10.1097/00005344-199801000-00006
Abstract
To assess the effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on plasma cholesterol concentrations and on platelet aggregation, lovastatin or fluvastatin, 40 mg daily, was given to hypercholesterolemic patients. After 24 weeks, plasma low-density lipoprotein (LDL) cholesterol concentrations were reduced by 37% after lovastatin therapy and 29% after fluvastatin therapy. The platelet cholesterol/phospholipid ratio was reduced by 33% and 26%, respectively. Platelet aggregation was significantly reduced by 12-15% (p < 0.01) after 4 weeks of therapy with either agent. Lovastatin or fluvastatin therapy reduced platelet aggregation through an in vivo hypocholesterolemic action on the platelet cholesterol content and also through a direct effect on platelet function, as a result of drug binding to the platelets. We also studied the effect of these HMG-CoA reductase inhibitors on LDL susceptibility to oxidation. LDL oxidation (induced by copper ions) was reduced by 31% after lovastatin therapy and by 37% after fluvastatin therapy. The inhibitory effect of HMG-CoA reductase inhibitors on LDL oxidation involved their stimulatory effect on the removal of LDL from the circulation and a direct binding effect of the drugs to the lipoprotein. Because HMG-CoA reductase inhibitors can inhibit platelet aggregation, macrophage foam cell formation, and LDL oxidation, major contributors to atherogenesis, the use of these drugs can significantly attenuate the atherosclerotic process.Keywords
This publication has 30 references indexed in Scilit:
- Lesioned Low-Density Lipoprotein in Atherosclerotic Apolipoprotein E-Deficient Transgenic Mice and in Humans Is Oxidized and AggregatedBiochemical and Biophysical Research Communications, 1995
- Increased Plasma and Lipoprotein Lipid Peroxidation in apo E-Deficient MiceBiochemical and Biophysical Research Communications, 1994
- Proteins derived from platelet α granules modulate the uptake of oxidized low density lipoprotein by macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Lipid-protein particles secreted from activated platelets reduce macrophage uptake of low density lipoproteinAtherosclerosis, 1991
- Platelet secreted lipoprotein-like particle is taken up by the macrophage scavenger receptor and enhances cellular cholesterol accumulationAtherosclerosis, 1991
- The effect of platelets on macrophage lipoprotein metabolismAtherosclerosis, 1988
- Platelet Lipoprotein InteractionsSeminars in Thrombosis and Hemostasis, 1988
- Role of platelets in cholesteryl ester formation by U-937 cells.JCI Insight, 1988
- New mechanism for foam cell generation in atherosclerotic lesions.JCI Insight, 1987
- Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patientsBiochemical Medicine, 1983